Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...
People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...
Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet and ...
INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...
GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results